Graft-versus-tumor effects on murine mammary carcinoma in a model of nonmyeloablative haploidentical stem cell transplantation

Bone Marrow Transplantation

Volumn 37, Issue 11, 2006, Pages 1043-1049

  Vanclee A ^a   van Gelder, M ^a   Schouten, H C ^a   Bos, G M J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Haploidentical; Keratinocyte growth factor; Nonmyeloablative; Stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; PALIFERMIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; FEMALE; GRAFT VERSUS HOST REACTION; LONG TERM CARE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE;

ANIMALS; FEMALE; FIBROBLAST GROWTH FACTOR 7; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HAPLOTYPES; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; RECOMBINANT PROTEINS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 33646795335     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705383     Document Type: Article

References (46)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. Can Cancer J Clin 2005; 55: 10-30.
2. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Can Cancer J Clin 2005; 55: 74-108.
4. Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer 2004; 101: 2843-2850.
5. Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA. Cancer mortality surveillance - United States, 1990-2000. MMWR Surveillance Summ 2004; 53: 1-108.
6. Nieto Y, Jones RB, Shpall EJ. Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol 2004; 26: 31-56.
7. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389.
8. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
9. Ueno NT, Rondón G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986-993.
10. Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 1996; 348: 1242-1243.
11. Martino R, Caballero MD, Canals C, San Miguel J, Sierra J, Rovira M et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 341-347.
12. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
13. Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
14. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
15. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatiic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
16. Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-441.
17. Bregni M, Bernardi M, Ciceri F, Peccatori J. Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol 2004; 26: 95-108.
18. Toh HC, Spitzer TR, Preffer F, Alexander SI, McAfee S, Dombkowski D et al. Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving nonmyeloablative conditioning and a haploidentical related allogeneic bone marrow transplant. Cytokines Cell Mol Ther 2002; 7: 43-47.
19. Satoh M, Miyamura K, Yamada M, Ishidoya S, Childs RW, Arai Y. Haploidentical, nonmyeloablative stem-cell transplantation for advanced renal-cell carcinoma. Lancet Oncol 2004; 5: 125-126.
20. Ikegame K, Kawakami M, Yamagami T, Maeda H, Onishi K, Taniguchi Y et al. HLA-haploidentical nonmyeloablative stem cell transplantation: Induction to tolerance without passing through mixed chimaerism. Clin Lab Haematol 2005; 27: 139-141.
21. Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-1759.
22. O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377-386.
23. Tamaki H, Ikegame K, Kawakami M, Fujioka T, Tsuboi A, Oji Y et al. Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia 2003; 17: 2052-2054.
24. Koenecke C, Shaffer J, Alexander SI, Preffer F, Dombkowski D, Siadman SL et al. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507. Exp Hematol 2003; 31: 911-923.
25. Morecki S, Yacovlev E, Diab A, Slavin S. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res 1998; 58: 3891-3895.
26. Prigozhina TB, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol 2002; 30: 89-96.
27. Panigrahi S, Morecki S, Yacovlev E, Gelfand Y, Kassir J, Slavin S. A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation. Exp Hematol 2004; 32: 756-764.
28. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998; 92: 3960-3967.
29. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS et al. Keratinocyte growth factor separates graft- versus-leukemia effects from graft-versus-host disease. Blood 1999; 94: 825-831.
30. Vanclée A, Lutgens LC, Oving EB, Deutz NE, Gijbels MJ, Schouten HC et al. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant 2005; 36: 907-915.
31. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 1978; 38: 3174-3181.
32. Or R, Ackerstein A, Nagler A, Amar A, Naparstek E, Varadi G et al. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: A clinical pilot study. Cytokines Cell Mol Ther 1998; 4: 1-6.
33. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886-3892.
34. Glass B, Nickelsen M, Dreger P, Claviez A, Hasenkamp J, Wulf G et al. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: The need for T cells early after transplantation to induce a graft-versus-lymphoma effect. Bone Marrow Transplant 2004; 34: 391-397.
35. Foley JE, Jung U, Miera A, Borenstein T, Mariotti J, Echhaus M et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol 2005; 175: 5732-5743.
36. Ruggeri L, Capanni M, Urbani E, Perruccio K, Schlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
37. Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci USA 1989; 86: 802-806.
38. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58: 933-939.
39. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM et al. Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 1992; 89: 246-250.
40. Johnson DE, Lu J, Chen H, Werner S, Williams LT. The human fibroblast growth factor receptor genes: A common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol 1991; 11: 4627-4634.
41. Bansal GS, Cox HC, Marsh S, Gomm JJ, Yiangou C, Luqmani Y et al. Expression of keratinocyte growth factor and its receptor in human breast cancer. Br J Cancer 1997; 75: 1567-1574.
42. Zang XP, Pento JT. Keratinocyte growth factor-induced motility of breast cancer cells. Clin Exp Metast 2000; 18: 573-580.
43. Nguyen TN, Zang XP, Pento JT. Keratinocyte growth factor stimulates the migration and proliferation of breast cancer cells in a culture wounding model. Pharmacol Res 2002; 46: 179-183.
44. Oelmann E, Haghgu S, Kulimova E, Mesters RM, Kienast J, Herbst H et al. Influence of keratinocyte growth factor on clonal growth of epithelial tumor cells, lymphoma and leukemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro. Int J Oncol 2004; 25: 1001-1012.
45. Taniguchi F, Harada T, Sakamoto Y, Yamauchi N, Yoshida S, Iwabe T et al. Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. J Clin Endocrinol Metab 2003; 88: 773-780.
46. Shan S, Robson ND, Cao Y, Qiao T, Li CY, Kontos CD et al. Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival. FASEB J 2004; 18: 326-328.